Navigation Links
XTENT Announces First Quarter 2008 Financial Results
Date:4/28/2008

innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing of its regulatory filings, the timing of the commercialization of its products and the timing of the release of its clinical trial data. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's annual report on Form 10-K for the year ended December 31, 2007. This annual report was filed with the SEC on March 17, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, ev
'/>"/>

SOURCE XTENT, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
2. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
3. Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)... July 10, 2014 Integrated Silicon Solution, Inc. ... memory and analog IC solutions, today announced that it ... 24, 2014, at 7:00 a.m. Pacific Time (10:00 a.m. ... the fiscal 2014 third quarter ended June 30, 2014. ... dial 1-888-556-4997 before 6:50 a.m. Pacific time on July ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... CINCINNATI, June 10, 2011 To address the need ... treat a variety of patient needs, Ethicon Endo-Surgery (EES), ... broadest spectrum of bariatric surgical solutions and innovative technologies ... (ASMBS) 28th Annual Meeting at the Gaylord Hotel and ...
... N.J., June 10, 2011 Insmed Incorporated (Nasdaq ... data through six treatment cycles (72 weeks total ... for ARIKACE® (liposomal amikacin for inhalation) in cystic ... infections.  The data were presented at the 34th ...
Cached Medicine Technology:Ethicon Endo-Surgery to Showcase Broadest Spectrum of Innovative Bariatric Surgical Options, Physician Best Practices and Mobile/Web-Based After-Care Patient Programs at ASMBS 2Ethicon Endo-Surgery to Showcase Broadest Spectrum of Innovative Bariatric Surgical Options, Physician Best Practices and Mobile/Web-Based After-Care Patient Programs at ASMBS 3Ethicon Endo-Surgery to Showcase Broadest Spectrum of Innovative Bariatric Surgical Options, Physician Best Practices and Mobile/Web-Based After-Care Patient Programs at ASMBS 4Ethicon Endo-Surgery to Showcase Broadest Spectrum of Innovative Bariatric Surgical Options, Physician Best Practices and Mobile/Web-Based After-Care Patient Programs at ASMBS 5Ethicon Endo-Surgery to Showcase Broadest Spectrum of Innovative Bariatric Surgical Options, Physician Best Practices and Mobile/Web-Based After-Care Patient Programs at ASMBS 6Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections 2Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections 3Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections 4Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections 5Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections 6
(Date:7/14/2014)... New research and analysis from the national ... examines toxic ingredients in tampons, a product used ... chemicals that may be found in the product’s absorptive ... put women’s health at risk. , According to ... , the potential impact of toxic chemical exposure from ...
(Date:7/13/2014)... (PRWEB) July 14, 2014 FORT LEE, N.J. ... tackle the modern approach to the science of tooth ... Implant. This book describes recent advances and techniques ... methodological approaches that benefit people who have lost all of ... inserted the first lower subperiosteal implant in 1940. ...
(Date:7/13/2014)... MA (PRWEB) July 14, 2014 MED-Ed ... presenting at our next conference, April 7+8 in Boston ... well attended at the recent event. Presentations by individuals ... 2014. , To review the types of sessions that ... , Submit your proposal today! , Conference ...
(Date:7/13/2014)... 14, 2014 Worldwide ladies are extremely ... Angeldress.co.uk has taken a different approach and has created ... are offered in more colour choices that responded directly ... brand of women’s special occasion apparels. The company’s pink ... specialists are working hard to create the best products ...
(Date:7/13/2014)... July 13, 2014 Ticket Down ... Madrid Tickets . For the fifth straight year (and ... will be held at American stadiums this summer. The tournament ... American soil. The eight teams are split into two groups ... the top two teams will compete to become champion. One ...
Breaking Medicine News(10 mins):Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:MED-Ed Facilities Conference Call for Speakers Open 2Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3
... Genomatix Software Inc., the newly incorporated subsidiary of Genomatix Software ... software licensing agreement with the NCI/NIH for the fourth consecutive ... history as the renewal was executed entirely between the US ... We are extremely pleased with our progress in putting the ...
... Rice University Psychology Professor Tony Ro has published its ... as synesthesia, in which stimulation of one sensory pathway ... pathway. , Ro,s paper, Feeling Sounds After a Thalamic ... the official journal of the American Neurological Association. The ...
... - Researchers at the Centre for Addiction and Mental ... and the risk of head and neck cancers, showing ... cancer risk. , According to CAMH Principal Investigator ... between alcohol consumption and an increased risk for cancer ...
... Drug Discovery Projects, REDWOOD CITY, Calif., Sept. ... announced today that it has obtained,commitments from several ... its common stock and warrants to purchase,approximately 2.6 ... proceeds of,approximately $23.7 million. The investors have agreed ...
... form of care, experts say , WEDNESDAY, Sept. ... issued new "performance measures" meant to boost patient enrollment ... heart attack patients aren,t getting the benefit of this ... set standards of excellence for these programs and are ...
... The close of summer traditionally,marks the return to ... fall,and holiday baking seasons. This year, in response to ... cooking is a growing,trend. A study published in the ... in kids, body mass index occur during the summer,months, ...
Cached Medicine News:Health News:Research at Rice may help explain aspects of synesthesia 2Health News:Research at Rice may help explain aspects of synesthesia 3Health News:Alcohol and cancer: is drinking the new smoking? 2Health News:Genelabs Technologies Announces Commitments to Raise $23.7 Million in a Registered Direct Financing 2Health News:Heart Attack Survivors Benefit From Rehab 2Health News:Just in Time for Fall Baking and Entertaining: The Sneaky Chef Tips Featuring Eagle Mills All-Purpose Flour made with Ultragrain(R) 2Health News:Just in Time for Fall Baking and Entertaining: The Sneaky Chef Tips Featuring Eagle Mills All-Purpose Flour made with Ultragrain(R) 3Health News:Just in Time for Fall Baking and Entertaining: The Sneaky Chef Tips Featuring Eagle Mills All-Purpose Flour made with Ultragrain(R) 4
... complete line of enteric disease ... and monoclonal/polyclonal antibody-based ELISA tests ... pathogens in fecal specimens. Our ... difficile, Entamoeba histolytica, Giardia, Cryptosporidium ...
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: